Media
Proactive Investors
Imugene receives A$11.7 million R&D tax refund
Proactive Investors
Imugene to receive A$11 million R&D tax refund for FY23
Proactive Investors
Imugene Phase 1 onCARlytics trial doses first patient in intratumoural combination arm
Proactive Investors
Imugene MAST trial delivers two-year complete response in bile tract cancer patient
Tech Investors
Imugene Hits Milestone with Orphan Drug Status for Bile Tract Cancer Therapy
Proactive Investors
Imugene secures FDA orphan drug designation for bile tract cancer treatment
The West Australian
Imugene gets crucial FDA nod for bile tract cancer drug
SmallCaps
Imugene reports promising Azer-cel results for advanced lymphoma patients in Phase 1b trial
Proactive Investors
Imugene fields positive results in Phase 1b trial of azer-cel CAR T therapy for blood cancer with three complete responses
Oncology Pipeline
Imugene goes for a cytokine boost
The Mentor with Mark Bouris (video)
Developing Cancer Cures through the ASX \ Going Public with Leslie Chong & Paul Hopper
Proactive Investors